Quarterly ResultMay 14, 2026, 04:27 PM
HCW Biologics Q1 Net Income $3.5M on $6.5M Revenue; Trimmune Deal
AI Summary
HCW Biologics Inc. reported a net income of $3.5 million for Q1 2026, a significant improvement from a $2.2 million net loss in Q1 2025, driven by $6.5 million in revenue from an exclusive worldwide licensing agreement with Beijing Trimmune Biotech Co., Ltd. The company also provided updates on its HCW9302 Phase 1 clinical study for alopecia areata, with preliminary data expected in H1 2026 and full data in Q4 2026. Despite these positive developments, the company issued a going concern warning and is appealing a Nasdaq delisting determination.
Key Highlights
- Q1 2026 net income was $3.5 million, compared to a $2.2 million net loss in Q1 2025.
- Q1 2026 revenues increased to $6.5 million from $5,065 in Q1 2025.
- Closed exclusive worldwide license for HCW11-006 with Trimmune for $3.5M cash and $3.5M equity.
- R&D expenses decreased 15% to $1.3 million in Q1 2026 from $1.5 million in Q1 2025.
- G&A expenses decreased 18% to $1.8 million in Q1 2026 from $2.2 million in Q1 2025.
- Completed a $1.5 million equity financing with an existing investor in February 2026.
- Preliminary clinical data for HCW9302 in alopecia areata expected in H1 2026, full data in Q4 2026.
- Company issued a going concern warning and is appealing a Nasdaq delisting determination.